AKROS PHARMA INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety Study of JTT-302 in Subjects With Low HDL-C Levels

Phase 2

Completed

Conditions: Dyslipidemia

Interventions: Drug: JTT-302

First Posted Date: 2008-09-09

Last Posted Date: 2013-02-04

Lead Sponsor: Akros Pharma Inc.

Target Recruit Count: 103

Registration Number: NCT00748852

Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels

Phase 2

Completed

Conditions: Dyslipidemia

Interventions: Drug: JTT-705 600 mg and simvastatin 40 mg
Drug: Placebo and simvastatin 40 mg

First Posted Date: 2008-06-03

Last Posted Date: 2008-06-03

Lead Sponsor: Akros Pharma Inc.

Target Recruit Count: 92

Registration Number: NCT00688558

Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia

Phase 2

Completed

Conditions: Type II Hyperlipidemia

Interventions: Drug: JTT-705 600 mg and pravastatin 40 mg
Drug: JTT-705 300 mg and pravastatin 40 mg
Drug: Placebo and pravastatin 40 mg

First Posted Date: 2008-06-03

Last Posted Date: 2008-06-03

Lead Sponsor: Akros Pharma Inc.

Target Recruit Count: 155

Registration Number: NCT00688896

Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels

Phase 2

Completed

Conditions: Dyslipidemia

Interventions: Drug: JTT-705 600 mg and atorvastatin 20 mg
Drug: Placebo and atorvastatin 20 mg

First Posted Date: 2008-06-03

Last Posted Date: 2008-06-03

Lead Sponsor: Akros Pharma Inc.

Target Recruit Count: 105

Registration Number: NCT00689442

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy